The Bifidobacterium longum subsp.infantis strain encodes the complete gene cluster needed to metabolize the full range of prebiotic human milk oligosaccharides (HMOs), complex sugars in human milk that are otherwise indigestible by the infant.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Product Information
Product Overview
The Bifidobacterium longum subsp.infantis strain encodes the complete gene cluster needed to metabolize the full range of prebiotic human milk oligosaccharides (HMOs), complex sugars in human milk that are otherwise indigestible by the infant.
Target
Bifidobacterium
Genus
Bifidobacterium
Application
Study and research
Type Strain
No
Culture Medium
BBL
Culture Conditions
37°C, Anaerobic
Risk Group
1
Product Format
Freeze-dried
Packaging
Ampoule tube
Storage
-80°C
Shelf Life
6 years
Target Introduction
Introduction
Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They are originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status.
Alternative Names
Bifidobacterium longum subsp.infantis
FAQsPublished Data Customer Reviews Related Products
What is the recommended inoculum size for Bifidobacterium longum subsp.infantis in laboratory cultures?
For laboratory experiments, it is recommended to use an inoculum size of approximately 1.8 × 10^10 CFU per serving. This concentration ensures effective colonization and metabolic activity, which are important for studying the probiotic's effects on the gut microbiome.
Which medium is suitable for culturing Bifidobacterium longum subsp.infantis ?
Bifidobacterium longum subsp.infantis is typically cultured in a medium that includes human milk oligosaccharides (HMOs), which closely mimic the conditions in the infant gut. This medium supports the specific metabolic requirements of the strain, facilitating its growth and activity.
How long does it take for Bifidobacterium longum subsp.infantis to reach log phase growth?
Under optimal anaerobic conditions at 37°C, Bifidobacterium longum subsp.infantis generally reaches log phase growth within 18-24 hours. It is important to monitor the growth curve to determine the optimal time for harvesting the cells.
What are the steps involved in preparing Bifidobacterium longum subsp.infantis for in vivo studies?
Preparation for in vivo studies involves growing the culture to the desired phase, harvesting the cells by centrifugation, and resuspending them in a carrier . This preparation method ensures consistent dosing and reliability in experimental protocols.
How can the viability of Bifidobacterium longum subsp.infantis be assessed before use?
The viability of Bifidobacterium longum subsp.infantis can be assessed using colony-forming unit (CFU) counts on selective agar plates. This method should be performed immediately before use to confirm the probiotic's viability and effectiveness in research applications.
For all panels, all available samples were analyzed from Study Day 14 (n = 13 control, n = 12 EVC001)
This study evaluated the safety and efficacy of Bifidobacterium longum subsp.infantis EVC001 in preterm infants within a Neonatal Intensive Care Unit. Thirty preterm infants, under 1,500 grams and/or less than 33 weeks gestation, were divided into two groups: one received daily feedings of EVC001, and the other served as the control. The trial aimed to determine the probiotic's ability to colonize the infant gut and enhance the utilization of human milk oligosaccharides (HMOs). Results showed that by day 14, infants receiving EVC001 exhibited a significant increase in B. infantis levels (mean = 9.7 Log10 CFU/µg fecal DNA), correlating with a notable reduction in fecal HMOs (ρ = −0.83, P < 0.0001), indicating improved HMO metabolism. No adverse events were linked to EVC001 administration, suggesting it is safe and well-tolerated. The findings underscore EVC001's potential in fostering beneficial gut microbiota and optimizing nutrient absorption from human milk, crucial for the growth and health of preterm infants.
Bajorek, S., Duar, R. M., et al. B. infantis EVC001 is well-tolerated and improves human milk oligosaccharide utilization in preterm infants in the neonatal intensive care unit. Frontiers in Pediatrics. 2022, 9: 795970. Distributed under Open Access license CC BY 4.0, without modification.
Exceptional Stability in Research
Creative Biolabs' Bifidobacterium longum subsp.infantis demonstrates exceptional stability, making it an ideal choice for prolonged studies in gastrointestinal health research.
Superior Viability for In-Depth Analysis
The superior viability of Bifidobacterium longum subsp.infantis from Creative Biolabs ensures consistent and reliable results, significantly enhancing the depth of microbiome analysis.
Enhanced Efficacy in Gut-Brain Axis Studies
In gut-brain axis research, Bifidobacterium longum subsp.infantis provides unparalleled efficacy, offering valuable insights and advancing our understanding of microbial interactions.
Consistent Performance in Metabolic Studies Bifidobacterium longum subsp.infantis stands out in metabolic studies, providing consistent performance and helping researchers uncover critical metabolic pathways.
High Potency in Microbiome Diversity Analysis
The high potency of Bifidobacterium longum subsp.infantis ensures comprehensive microbiome diversity analysis, setting a new standard for quality in microbial research.
Click the button below to contact us or submit your feedback about this product.
